Form 4: Y-mAbs Therapeutics Executive Thomas Gad Reports Stock Sales

Thomas Gad, Chief Business Officer of Y-mAbs Therapeutics, reports the sale of company stock in multiple transactions.

Summary

• Thomas Gad, the Chief Business Officer of Y-mAbs Therapeutics, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• On May 21, 2024, Gad sold 25,000 shares of common stock at a price of $12 per share.
• On May 23, 2024, he sold an additional 7,351 shares at a weighted average price of $13.00 to $13.01 per share.
• Following these transactions, Gad directly owns 158,700 shares and indirectly owns 232,681 shares through GAD Enterprises LLC and 60,000 shares through his children.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock sales by an executive. It doesn't inherently indicate positive or negative sentiment about the company's future.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in the pharmaceutical industry. Investors often monitor these filings for insights into management's perspective on the company's stock value and future prospects.

Stakeholder Impact

• Shareholders may interpret the stock sales as a lack of confidence by the executive, although it could also be for personal financial reasons.

Key Dates